Examining and comparing the effect of zintoma versus ondansetron

Investigating and comparing the anti-nausea and vomiting effect of Zintoma (ginger) capsules against ondansetron or granisetron in children over 6 years old undergoing chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231010059683N1

Enrollment

128

Registered

2023-11-07

Start date

2023-02-19

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and vomiting. haematemesis (K92.0)haematemesisneonatal (P54.0)vomiting (of):excessive, in pregnancy (O21.-)following gastrointestinal surgery (K91.0)newborn (P92.0)psychogenic (F50.5)

Interventions

Intervention 1: Intervention group:Patients received Zyntoma capsules 250 ml every 8 hours in a 3-day treatment period (Goldaru Pharmaceutical Co.). Intervention 2: Control group: Patients in the cont

Eligibility

Sex/Gender

All

Age

6 Years to 18 Years

Inclusion criteria

Inclusion criteria: Patients undergoing chemotherapy Children over 6 years old

Exclusion criteria

Exclusion criteria: Heavy chemotherapy Discontinuation of chemotherapy for any reason

Design outcomes

Primary

Measure	Time frame
Primary outcome: treatment response which includes: presence/absence of chemotherapy-related nausea and vomiting. Timepoint: 3 days after treatment. Method of measurement: patient file; patient question.	—

Secondary

Measure	Time frame
Secondary outcome: patient's appetite after treatment. Timepoint: 3 days After treatment. Method of measurement: by Asking the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamirarezayi

Tehran University of Medical Sciences

Samirarezayi581@yahoo.com+98 21 6147 2353

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026